Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: Effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells

Leukemia

Volumn 27, Issue 2, 2013, Pages 451-463

  Bolzoni, M ^a   Donofrio, G ^a   Storti, P ^a   Guasco, D ^a   Toscani, D ^a   Lazzaretti, M ^a   Bonomini, S ^a   Agnelli, L ^b   Capocefalo, A ^a   Dalla Palma, B ^a   Neri, A ^b   Nicolini, F ^a   Lisignoli, G ^c   Russo, F ^a   Colla, S ^d   Aversa, F ^a   Giuliani, N ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; ROR2 PROTEIN; SMALL INTERFERING RNA; SYNDECAN 1; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ARTICLE; BONE DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MESENCHYMAL STROMA CELL; MOLECULAR DYNAMICS; MYELOMA CELL; OSTEOBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOGENESIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 84873567746     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.190     Document Type: Article

References (38)

1. Raje N, Roodman GD. AdVances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278-1286.
2. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992-3996.
3. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483.
4. Giuliani N, Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma 2007; 48: 2323-2329.
5. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19-39.
6. Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209.
7. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012; 492: 1-18.
8. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008; 111: 2833-2842.
9. Qiang YW, Shaughnessy Jr JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008; 112: 374-381.
10. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379.
11. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192-199.
12. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr JD. Antibodybased inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-2111.
13. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
14. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009; 113: 517-525.
15. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665-7674.
16. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004; 93: 1210-1230.
17. De Boer J, Siddappa R, Gaspar C, Van Apeldoorn A, Fodde R, Van Blitterswijk C. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 2004; 34: 818-826.
18. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4: 68-75.
19. Kühl M. Non-canonical Wnt signaling in Xenopus: regulation of axis formation and gastrulation. Semin Cell Dev Biol 2002; 13: 243-249.
20. Liu F, Kohlmeier S, Wang CY. Wnt signaling and skeletal development. Cell Signal 2008; 20: 999-1009.
21. Baksh D, Boland GM, Tuan RS. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 2007; 101: 1109-1124.
22. Baksh D, Tuan RS. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 2007; 212: 817-826.
23. Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 2007; 282: 30938-30948.
24. Santos A, Bakker AD, de Blieck-Hogervorst JM, Klein-Nulend J. WNT5A induces osteogenic differentiation of human adipose stem cells via rho-associated kinase ROCK. Cytotherapy 2010; 12: 924-932.
25. Minami Y, Oishi I, Endo M, Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn 2010; 239: 1-15.
26. Liu Y, Rubin B, Bodine PV, Billiard J. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 2008; 105: 497-502.
27. Billiard J, Way DS, Seestaller-Wehr LM, Moran RA, Mangine A, Bodine PV. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 2005; 19: 90-101.
28. Liu Y, Ross JF, Bodine PV, Billiard J. Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. Mol Endocrinol 2007; 21: 3050-3061.
29. Liu Y, Bhat RA, Seestaller-Wehr LM, Fukayama S, Mangine A, Moran RA et al. The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. Mol Endocrinol 2007; 21: 376-387.
30. Qiang YW, Chen Y, Hu B, Qiang W, Hueck C, Yaccoby S et al. Secreted frizzledrelated protein-3 (sFRP3) is produced by myeloma cells and augments wnt3ainduced differentiation of mesenchymal stem cells and OPG production in osteoblasts. Blood 2011; 118: 808a.
31. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005; 11: 880-885.
32. Penolazzi L, Lisignoli G, Lambertini E, Torreggiani E, Manferdini C, Lolli A et al. Transcription factor decoy against NFATc1 in human primary osteoblasts. Int J Mol Med 2011; 28: 199-206.
33. D'Souza S, Del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011; 118: 6871-6880.
34. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165.
35. Fromigué O, HaÿE, Barbara A, Marie PJ. Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem 2010; 285: 25251-25258.
36. Lisignoli G, Toneguzzi S, Piacentini A, Cristino S, Grassi F, Cavallo C et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003; 194: 71-79.
37. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uzé G. Interferon-alpha and-beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 2005; 102: 11917-11922.
38. Rauner M, Stein N, Winzer M, Goettsch C, Zwerina J, Schett G et al. WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 2012; 27: 575-585.